Suppr超能文献

表皮生长因子受体激活后,Eps15被招募至质膜,并在受体内化过程中定位于内吞途径的组分。

Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization.

作者信息

Torrisi M R, Lotti L V, Belleudi F, Gradini R, Salcini A E, Confalonieri S, Pelicci P G, Di Fiore P P

机构信息

Dipartimento di Medicina Sperimentale e Patologia, University of Roma "La Sapienza," Rome 00161, Italy.

出版信息

Mol Biol Cell. 1999 Feb;10(2):417-34. doi: 10.1091/mbc.10.2.417.

Abstract

Eps15 is a substrate for the tyrosine kinase of the epidermal growth factor receptor (EGFR) and is characterized by the presence of a novel protein:protein interaction domain, the EH domain. Eps15 also stably binds the clathrin adaptor protein complex AP-2. Previous work demonstrated an essential role for eps15 in receptor-mediated endocytosis. In this study we show that, upon activation of the EGFR kinase, eps15 undergoes dramatic relocalization consisting of 1) initial relocalization to the plasma membrane and 2) subsequent colocalization with the EGFR in various intracellular compartments of the endocytic pathway, with the notable exclusion of coated vesicles. Relocalization of eps15 is independent of its binding to the EGFR or of binding of the receptor to AP-2. Furthermore, eps15 appears to undergo tyrosine phosphorylation both at the plasma membrane and in a nocodazole-sensitive compartment, suggesting sustained phosphorylation in endocytic compartments. Our results are consistent with a model in which eps15 undergoes cycles of association:dissociation with membranes and suggest multiple roles for this protein in the endocytic pathway.

摘要

Eps15是表皮生长因子受体(EGFR)酪氨酸激酶的底物,其特征在于存在一种新型蛋白质:蛋白质相互作用结构域,即EH结构域。Eps15还能稳定结合网格蛋白衔接蛋白复合物AP - 2。先前的研究表明eps15在受体介导的内吞作用中起重要作用。在本研究中,我们发现,在EGFR激酶激活后,eps15会发生显著的重新定位,包括1)最初重新定位到质膜,以及2)随后在胞吞途径的各种细胞内区室中与EGFR共定位,但明显不包括被膜小泡。eps15的重新定位与其与EGFR的结合或受体与AP - 2的结合无关。此外,eps15似乎在质膜和对诺考达唑敏感的区室中都发生酪氨酸磷酸化,这表明在内吞区室中存在持续的磷酸化。我们的结果与一种模型一致,即eps15经历与膜的结合:解离循环,并表明该蛋白在胞吞途径中具有多种作用。

相似文献

引用本文的文献

5
Busting the Breast Cancer with AstraZeneca's Gefitinib.阿斯利康的吉非替尼抗击乳腺癌
Adv Pharmacol Pharm Sci. 2023 Dec 4;2023:8127695. doi: 10.1155/2023/8127695. eCollection 2023.

本文引用的文献

2
Adaptins.衔接蛋白
Trends Cell Biol. 1992 Oct;2(10):293-7. doi: 10.1016/0962-8924(92)90118-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验